PositiveID Corp., a developer of diabetes management medical technologies, announced that it has received clearance from the U.S. Food and Drug Administration for its iglucose™ mobile health technology. The iglucose technology revolutionizes the way in which people with diabetes manage their condition; by communicating glucose readings from data-capable glucometers to the iglucose portal, family members, caregivers and healthcare professionals can all access the important data.
PositiveID’s technology responds to the call by the American Diabetes Association and the CDC for those affected by diabetes to self-monitor and give glucose readings to their healthcare professionals. An American Association of Diabetes Educators (“AADE”) positioning statement revealed that self-monitoring is the best way for people with diabetes to assess the ongoing efficacy of all aspects of the diabetes management regimen. iglucose eliminates manual recordkeeping and empowers individuals with diabetes to be more engaged in the self-management of their condition.
The iglucose system collects and transmits stored data from a variety of FDA-cleared blood glucose meters such as the LifeScan® OneTouch®, marketed by Johnson & Johnson, and Nipro Diagnostic™ True™ monitoring systems to a secure database via wireless cellular technology. Readings can be shared automatically via text message, email or fax. iglucose does not require the use of a cell phone or a wireless plan.
William J. Caragol, Chief Executive Officer of PositiveID stated, “iglucose is a safe, flexible, convenient, cost-effective and straightforward solution that we believe will revolutionize the way people with diabetes manage their condition. iglucose represents an opportunity to help decrease costs to our healthcare system by helping to improve disease management and patient compliance. This FDA clearance is an important validation of our product offering for PositiveID and we will work diligently to make iglucose available to everyone affected by diabetes in the near future.”
PositiveID attended the most recent AADE conference and surveyed healthcare professionals regarding the interest in the iglucose system. Survey results showed that 83% of diabetes educators believe using iglucose would improve patient outcomes; and 82% believe using iglucose would improve patient consults. Further, 76% of diabetes educators would recommend iglucose to their patients.
For more information on iglucose, please visit www.iglucose.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment